Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP).
We report two patients with myopathy associated with anti-signal recognition particle Ab, refractory to conventional therapy, who were treated with prednisone and plasma exchange, followed by rituximab. A marked response was observed in both patients, with partial to complete recovery of muscle strength, which was sustained.
Arlet
Jean-Benoit
JB
Department of Internal Medicine, Faculty of Medicine, Cochin Hospital, Paris-Descartes University, Assistance Publique-Hôpitaux de Paris, AP-HP, Paris, France.
Dimitri
Dalia
D
Pagnoux
Christian
C
Boyer
Olivier
O
Maisonobe
Thierry
T
Authier
François-Jérome
FJ
Bloch-Queyrat
Coralie
C
Goulvestre
Claire
C
Heshmati
Farhad
F
Atassi
Marielle
M
Guillevin
Loïc
L
Herson
Serge
S
Benveniste
Olivier
O
Mouthon
Luc
L
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002985:Clinical Protocols / Q000592:standards; D018450:Disease Progression; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D008297:Male; D018482:Muscle, Skeletal / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology; D009135:Muscular Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D010951:Plasma Exchange / Q000379:methods*; D011241:Prednisone / Q000008:administration & dosage*; D000069283:Rituximab; D018271:Signal Recognition Particle / Q000276:immunology*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D007155:Immunologic Factors; D018271:Signal Recognition Particle; D000069283:Rituximab; D011241:Prednisone